We are live on ! Find out more
PALI icon

Palisade Bio
PALI

6 hedge funds and large institutions have $1.41M invested in Palisade Bio in 2017 Q3 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 1

22% more call options, than puts

Call options by funds: $67K | Put options by funds: $55K

20% more funds holding

Funds holding: 5 → 6 (+1)

0% more ownership

Funds ownership: 0% → 0% (+0%)

73% less capital invested

Capital invested by funds: $5.14M → $1.41M (-$3.73M)

Holders
6
Holders Change
+1
Holders Change %
+20%
% of All Funds
0.15%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
2
Increased
1
Reduced
–
Closed
1
Calls
$67K
Puts
$55K
Net Calls
+$12K
Net Calls Change
-$385K

Top Buyers

Rank Fund Capital Flow
1
ARTA
A.R.T. Advisors
New York
+$209K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$209K
3
VF
Virtu Financial
New York
+$209K

Top Sellers

Rank Fund Capital Flow
1
William Blair & Company
William Blair & Company
Illinois
-$506K
2
Commonwealth Equity Services
Commonwealth Equity Services
Massachusetts
-$89K
3
FO
FT Options
Illinois
-$15K
4
Creative Planning
Creative Planning
Kansas
-$2K
5
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance)
Ontario, Canada
-$1K

PALI Hedge Fund Activity: Q3 2017 in Review

6 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Palisade Bio (PALI) for Q3 2017, worth a combined $1.41M — down 73% from $5.14M a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new PALI positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 0 trimmed.

The largest buyer was A.R.T. Advisors, opening a new position worth an estimated $209K. The largest seller was William Blair & Company, exiting entirely with an estimated $506K sold.

  • 6 institutional investors held Palisade Bio (PALI) as of Q3 2017, up from 5 in Q2 2017.
  • Funds reported $1.41M of Palisade Bio stock for Q3 2017, down 73% quarter-over-quarter.
  • 2 funds opened new Palisade Bio positions in Q3 2017 and 1 closed out, a net change of +1 holder.
  • The largest Palisade Bio buyer in Q3 2017 was A.R.T. Advisors, an estimated $209K added.
  • The largest Palisade Bio seller in Q3 2017 was William Blair & Company, an estimated $506K sold.

Based on aggregated 13F filings for Q3 2017.